F. Gesuete, F. Ferri, S. Muñoz Declara, L. Luciani, F. Tirrito, G. Zanna
American Journal of Veterinary Research, Nov 20:1-7, 2025
Objective: To describe the clinical effects of photobiomodulation (PBM) therapy using a dual-wavelength near-infrared laser (Multiwave Locked System; Asa Srl) as adjunctive treatment in dogs with calcinosis cutis (CC).
Animals: 3 client-owned dogs presented to 2 referral veterinary hospitals from 2022 through 2023 were included. Cases were identified retrospectively via medical record review. Inclusion criteria were clinical and cytological features consistent with CC and histopathological examination when available, diagnosis of hyperadrenocorticism (HAC) based on clinical signs and diagnostic workup, availability of sufficient clinical records and photographic documentation, and owner consent for PBM therapy. Photobiomodulation was applied following a standardized protocol in scanning mode with a 2-cm collimated handpiece (approx 3-cm2 spot): 3 sessions during week 1, every 72 hours in week 2, and then weekly with 4 J/cm2 at the first session and 2.03 J/cm2 thereafter.
Clinical presentation: Included dogs were a 5-year-old male Labrador Retriever and an 8-year-old male English Bulldog with naturally occurring HAC and a 3-year-old female German Shepherd with iatrogenic HAC. All presented with dermatologic lesions compatible with CC (erythematous-crusted plaques, erosive-ulcerative lesions, and/or papules).
Results: 2 dogs achieved complete lesion resolution with hair regrowth within 7 to 12 weeks; the third showed partial improvement. No adverse events occurred.
Clinical relevance: Findings, although based on a limited number of cases, suggest a potential supportive role for PBM in the management of CC. Controlled studies are warranted to establish standardized treatment parameters and clarify its role in CC.
L'accesso alla visualizzazione dei prodotti e al materiale informativo è riservato agli operatori del settore in ottemperanza alla legislazione vigente. ASA richiede di qualificarsi come operatore del settore per procedere con la navigazione.
Decreto Legislativo 24 febbraio 1997, n°46 Articolo 21
1. E' vietata la pubblicità verso il pubblico dei dispositivi che, secondo disposizioni adottate con decreto del Ministro della Sanità, possono essere venduti soltanto su prescrizione medica o essere impiegati eventualmente con l'assistenza di un medico o di altro professionista sanitario.
2. La pubblicità presso il pubblico dei dispositivi diversi da quelli di cui al comma 1 è soggetta ad autorizzazione del Ministero della Sanità. Sulle domande di autorizzazione esprime parere la Commissione di esperti prevista dall'articolo 6, comma 3, del decreto legislativo
30 dicembre 1992, n. 541, che a tal fine è integrata da un rappresentante del Dipartimento del Ministero della Sanità competente in materia di dispositivi medici e da uno del Ministero dell'Industria, del commercio e dell'artigianato.
Some of the contents of this website cannot be disclosed in the USA and its territories and possesions, for regulatory reasons. If you are a US resident, please click on the button here below and access ASA's distributor website for North America.